Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$9.14M+870.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harpreet Singh
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 704
- Beta
- 1.33
- Country
- DE
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 3.30
Financials
Revenue
$9.14M+870.2%Net Income
$-62.49MEBITDA
$-59.51MFree Cash Flow
$-62.08M-1330.7%EPS (diluted)
$-0.46Shares Outstanding (diluted)
136.68M+117.3%Operating Expenses
$76.35MCash & Debt
$393.19MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $48.27M | $-196.45M | $-1.54 |
| 2024 | $155.84M | $15.22M | $0.14 |
| 2023 | $54.00M | $-94.65M | $-1.18 |
| 2022 | $172.83M | $27.70M | $0.56 |
| 2021 | $34.76M | $-93.33M | $-1.48 |
| 2020 | $31.25M | $-211.28M | $-4.40 |
| 2019 | $18.45M | $-31.74M | $-0.50 |
| 2018 | $3.77M | $-31.44M | $-0.50 |
Valuation
IMTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
138+175.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·41d ago·Neutral
…l Label Expansion For Uveal Melanoma Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed TCR therapy in phase 3 SUPRAME for 2nd-line melanoma, with final PFS data expected in H1 2027. Positive phase 1b data [56% cORR, 6.1m PFS] and expansion into metastatic uveal melanoma support label expansion and broader PRAME pipeline ambitions.
View source ↗ - Newsglobenewswire.com·42d ago·Negative
Immatics Announces $150 Million Underwritten Offering Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares …
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Immatics Announces Second Quarter 2026 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today provided a business update and reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Tue, Nov 17(in 6 weeks)
Consensus estimate $-0.50 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 18$-0.53 vs $-0.48miss
- Tue, May 12$-0.50 vs $-0.42miss
- Thu, Mar 5$-0.34 vs $-0.48beat
- Mon, Nov 17$-0.49 vs $-0.44miss
- Wed, Aug 13$-0.66 vs $-0.38miss
- Tue, May 13$-0.35 vs $-0.39beat
Estimates and results for IMTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMTX officers and directors.
- Bought
- $7.5m
- Sold
- —
1 trade
0 trades
- Perceptive Advisors Llcbought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.